A group of patients taking Calquence in addition to receiving standard care didn’t show fewer deaths or respiratory failures.
“While the [trial] results are disappointing, we remain committed to advancing science that helps patients during this unprecedented global pandemic, including clinical trials for the AstraZeneca Oxford coronavirus vaccine and our long-acting antibody combination,” said José Baselga, AstraZeneca’s executive vice president of oncology research and development.
Calquence is one of many existing drugs approved to treat other conditions that have been tested against COVID-19.
AstraZeneca said this trial won’t have any effect on Calquence’s approval for treating blood cancers, and no new safety concerns were found.
Read the full news release here.
More articles on pharmacy:
Florida surveying pharmacies, hospitals on vaccine storage capabilities
18 generic drugmakers unite to speed access to COVID-19 treatments
Cardinal Health, CDC partner to give pharmacies COVID-19 vaccine access
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.